Resolution Agonist 15-epi-Lipoxin A4 Programs Early Activation of Resolving Phase in Post-Myocardial Infarction Healing

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Kain, Vasundhara ^a   Liu, Fei ^b   Kozlovskaya, Veronika ^b   Ingle, Kevin A ^a   Bolisetty, Subhashini ^c   Agarwal, Anupam ^c   Khedkar, Santosh ^d   Prabhu, Sumanth D ^a   Kharlampieva, Eugenia ^b   Halade, Ganesh V ^a  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d ChemBio Discovery Inc Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOXIN; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HEART INFARCTION; HEART VENTRICLE; HEART VENTRICLE REMODELING; IMMUNOLOGY; LUNG; MACROPHAGE; MALE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; HEART VENTRICLES; LIPOXINS; LUNG; MACROPHAGES; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 85028553845     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10441-8     Document Type: Article

References (50)

1. Frangogiannis, N. G. Regulation of the inflammatory response in cardiac repair. Circulation research 110, 159-173, doi: 10.1161/CIRCRESAHA.111.243162 (2012).
2. Damman, K. & Testani, J. M. The kidney in heart failure: an update. Eur Heart J 36, 1437-1444, doi: 10.1093/eurheartj/ehv010 (2015).
3. Silverman, H. S. & Pfeifer, M. P. Relation between use of anti-inflammatory agents and left ventricular free wall rupture during acute myocardial infarction. Am J Cardiol 59, 363-364 (1987).
4. Saito, T. et al. Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor. Can J Physiol Pharmacol 81, 114-119, doi: 10.1139/y03-023 (2003).
5. Choudhury, D. & Ahmed, Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2, 80-91, doi: 10.1038/ncpneph0076 (2006).
6. Skyschally, A. et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circulation research 100, 140-146, doi: 10.1161/01.RES.0000255031.15793.86 (2007).
7. Mann, D. L. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circulation research 116, 1254-1268, doi: 10.1161/CIRCRESAHA.116.302317 (2015).
8. Tourki, B. & Halade, G. Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. doi: 10.1096/fj.201700109R (2017).
9. French, B. A. & Kramer, C. M. Mechanisms of Post-Infarct Left Ventricular Remodeling. Drug Discov Today Dis Mech 4, 185-196, doi: 10.1016/j.ddmec.2007.12.006 (2007).
10. Sutton, M. G. & Sharpe, N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981-2988 (2000).
11. Emami, H. et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 8, 121-130, doi: 10.1016/j.jcmg.2014.10.009 (2015).
12. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (New York, N.Y.) 325, 612-616, doi: 10.1126/science.1175202 (2009).
13. Kain, V., Prabhu, S. D. & Halade, G. V. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic research in cardiology 109, 444, doi: 10.1007/s00395-014-0444-7 (2014).
14. Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6, 1191-1197, doi: 10.1038/ni1276 (2005).
15. Kain, V. et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol 84, 24-35, doi: 10.1016/j.yjmcc.2015.04.003 (2015).
16. Serhan, C. N. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73, 141-162, doi: 10.1016/j.plefa.2005.05.002 (2005).
17. Claria, J. & Serhan, C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proceedings of the National Academy of Sciences of the United States of America 92, 9475-9479 (1995).
18. Serhan, C. N. & Chiang, N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632-640, doi: 10.1016/j.coph.2013.05.012 (2013).
19. Spite, M. & Serhan, C. N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circulation research 107, 1170-1184, doi: 10.1161/CIRCRESAHA.110.223883 (2010).
20. Roach, K. M., Feghali-Bostwick, C. A., Amrani, Y. & Bradding, P. Lipoxin A4 Attenuates Constitutive and TGF-beta1-Dependent Profibrotic Activity in Human Lung Myofibroblasts. J Immunol 195, 2852-2860, doi: 10.4049/jimmunol.1500936 (2015).
21. Reina-Couto, M. et al. Impaired resolution of inflammation in human chronic heart failure. Eur J Clin Invest 44, 527-538, doi: 10.1111/eci.12265 (2014).
22. Chaudhury, A. et al. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration. Int J Pharm 430, 167-175, doi: 10.1016/j.ijpharm.2012.04.036 (2012).
23. Castile, J. D. & Taylor, K. M. Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion. Int J Pharm 188, 87-95 (1999).
24. Nii, T. & Ishii, F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm 298, 198-205, doi: 10.1016/j.ijpharm.2005.04.029 (2005).
25. Frangogiannis, N. G. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11, 255-265, doi: 10.1038/nrcardio.2014.28 (2014).
26. Maderna, P. et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 4240-4249, doi: 10.1096/fj.10-159913 (2010).
27. Petri, M. H. et al. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovascular research 105, 65-74, doi: 10.1093/cvr/cvu224 (2015).
28. Lee, H. Y. et al. Activation of human monocytes by a formyl peptide receptor 2-derived pepducin. FEBS Lett 584, 4102-4108, doi: 10.1016/j.febslet.2010.08.036 (2010).
29. Stenfeldt, A. L. et al. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation 30, 224-229, doi: 10.1007/s10753-007-9040-4 (2007).
30. Fiore, S. & Serhan, C. N. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry 34, 16678-16686 (1995).
31. Chiang, N., Hurwitz, S., Ridker, P. M. & Serhan, C. N. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol 26, e14-17, doi: 10.1161/01.ATV.0000196729.98651.bf (2006).
32. Chen, K. et al. Signal relay by CC chemokine receptor 2 (CCR2) and formylpeptide receptor 2 (Fpr2) in the recruitment of monocyte-derived dendritic cells in allergic airway inflammation. J Biol Chem 288, 16262-16273, doi: 10.1074/jbc.M113.450635 (2013).
33. Lee, T. H. et al. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond) 77, 195-203 (1989).
34. Birnbaum, Y. et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 114, 929-935, doi: 10.1161/CIRCULATIONAHA.106.629907 (2006).
35. Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proceedings of the National Academy of Sciences of the United States of America 107, 1660-1665, doi: 10.1073/pnas.0907342107 (2010).
36. Prieto, P. et al. Activation of autophagy in macrophages by pro-resolving lipid mediators. Autophagy 11, 1729-1744, doi: 10.1080/15548627.2015.1078958 (2015).
37. Fielding, C. A. et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 181, 2189-2195 (2008).
38. Oliveira, S. H., Canetti, C., Ribeiro, R. A. & Cunha, F. Q. Neutrophil migration induced by IL-1beta depends upon LTB4 released by macrophages and upon TNF-alpha and IL-1beta released by mast cells. Inflammation 31, 36-46, doi: 10.1007/s10753-007-9047-x (2008).
39. Fearon, W. F. & Fearon, D. T. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 117, 2577-2579, doi: 10.1161/CIRCULATIONAHA.108.772491 (2008).
40. Liu, P. P. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol 24(Suppl B), 25B-29B (2008).
41. Han, W. K., Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62, 237-244, doi: 10.1046/j.1523-1755.2002.00433.x (2002).
42. Wu, S. H., Chen, X. Q., Liu, B., Wu, H. J. & Dong, L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol 168, 172-178, doi: 10.1111/j.1365-2133.2012.11177.x (2013).
43. Voorhees, A. P. et al. Building a better infarct: Modulation of collagen cross-linking to increase infarct stiffness and reduce left ventricular dilation post-myocardial infarction. Journal of molecular and cellular cardiology 85, 229-239, doi: 10.1016/j.yjmcc.2015.06.006 (2015).
44. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews. Drug discovery 9, 615-627, doi: 10.1038/nrd2591 (2010).
45. Soema, P. C., Willems, G. J., Jiskoot, W., Amorij, J. P. & Kersten, G. F. Predicting the influence of liposomal lipid composition on liposome size, zeta potential and liposome-induced dendritic cell maturation using a design of experiments approach. Eur J Pharm Biopharm 94, 427-435, doi: 10.1016/j.ejpb.2015.06.026 (2015).
46. Buyens, K. et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release 158, 362-370, doi: 10.1016/j.jconrel.2011.10.009 (2012).
47. Landesman-Milo, D. & Peer, D. Altering the immune response with lipid-based nanoparticles. J Control Release 161, 600-608, doi: 10.1016/j.jconrel.2011.12.034 (2012).
48. Layoun, A., Samba, M. & Santos, M. M. Isolation of murine peritoneal macrophages to carry out gene expression analysis upon Toll-like receptors stimulation. J Vis Exp, e52749, doi: 10.3791/52749 (2015).
49. Ma, Y. et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circulation research 112, 675-688, doi: 10.1161/CIRCRESAHA.111.300502 (2013).
50. Halade, G. V., Kain, V., Black, L. M., Prabhu, S. D. & Ingle, K. A. Aging dysregulates D- and E-series resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction. Aging, doi: 10.18632/aging.101077 (2016).